IP Library Granted Patent US 6,916,919
Granted Patent B2
US 6,916,919 · App. 10/473,239 · Granted Jul 12, 2005

Isolation of DNA molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,916,919
App. No.
10/473,239
Granted
Jul 12, 2005
Kind
B2
Abstract

The present invention relates to a process for separating nucleic acid molecules, preferably open circular and supercoiled plasmid DNA and RNA molecules from each other, comprising the steps of providing a solution comprising the molecules; adsorbing the molecules to adsorbing groups on a carrier; and optionally washing the column with a suitable solution. The present process is especially suitable for large-scale isolation of supercoiled ccc DNA to be used in gene therapy.

Claims (19)

1. A process for separating nucleic acid molecules form a solution, comprising the steps of:

(a) subjecting a mixture of nucleic acid molecules to a matrix of a carrier surface with an S-aryl ligand containing a pyridyl moiety attached thereto, such that the nucleic acids are adsorbed onto said S-aryl ligand containing a pyridyl moiety;

(b) subjecting the nucleic acid molecules to an elution step;

(c) isolating one or more different fractions containing the different nucleic acid molecules; and

(d) optionally washing the carrier with a washing solution wherein the nucleic acid molecules include open circle plasmid DNA, closed circle complex plasmid DNA, genomic DNA and RNA.

2. The process of claim 1 , further comprising an initial step of lysing cells which express the nucleic acid molecules to provide the solution comprising nucleic acid molecules.

3. The process of claim 1 , which further comprises a step of eluting the nucleic acid molecules by contacting with an eluent.

4. The process of claim 1 , wherein the carrier is an inorganic matrix.

5. The process of claim 4 , wherein the carrier is glass.

6. The process of claim 4 , wherein the carrier is a zeolite.

7. The process of claim 4 , wherein the carrier is a silica.

8. The process of claim 1 , wherein the carrier is an organic matrix.

9. The process of claim 8 , wherein the carrier is a resin or polymer.

10. The process of claim 9 , wherein the carrier is selected from the group consisting of agarose, cross-linked agarose, dextran, polystyrene/divinylbenzene, coated polystyrene, acrylic polymer, dextran acrylic polymer, vinylic grafted polymer and vinylic polymer.

11. The process of claim 9 , wherein the carrier includes one or more silica based resins in the form of silica-dextran, silica-acrylic polymer or silica-polyethyleneimine.

12. The process of claim 1 , wherein the carrier is present as a membrane which comes in contact with the nucleic acid molecule mixture.

13. The process of claim 1 , wherein the carrier is present as a chromatography matrix in a column through which the nucleic acid molecule mixture is passed.

14. The process of claim 1 , wherein the S-aryl ligand is a pyridyl-S ligand having the S-moiety bound in 2 (ortho) or 3 (meta) position to the pyridyl nitrogen atom.

15. The process of claim 14 , wherein the S-aryl ligand is separated from the pyridyl moiety via an alkylene chain having 1 to 7 carbon atoms.

Assignments (2)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →